Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Highlights - June 2016


Last month (May 2016), we released chemPK™ v.2 for predicting human pharmacokinetics directly from chemical structure. The new version has enhanced functionality and enables both IV and oral administration to be simulated as well as repeat dose regimens. In June, we've built further on that service with chemTarget – a virtual screening tool for predicting biological target interaction from chemical structure. By integrating chemTarget with chemPK™, an extremely powerful system has been developed which can provide in-depth biological target engagement parameters.

Endocrine disruption is a hot topic, with several regulatory authorities planning reform in terms of the testing requirements. In June, we launched our Androgen Receptor modulation assay. This assay uses high content imaging which enables androgen receptor translocation from the cytoplasm to the nucleus to be visualised and measured using fluorescently tagged proteins. As well as androgen receptor activation, the assay can also detect androgen receptor antagonists which has application in drug discovery screening for prostate cancer therapies. The new assay complements our existing screening and regulatory endocrine disruption services.

Amidst these launches, research has not slowed down. We have presented our research at the Clinically Relevant Drug Transporters meeting in Berlin and ISSX in South Korea.

chemTarget - biological target interaction directly from chemical structure

chemTarget uses unique pattern recognition software to build models from existing data sets and can predict interaction indicators such as binding affinity and inhibition constants directly from chemical structure.

Learn more
In silico ADME prediction
New Androgen Receptor modulation assay for endocrine disruption testing

The Androgen Receptor (AR) modulation assay detects agonists and antagonists of the AR by monitoring translocation from the cytoplasm to the nucleus. It can be used for drug discovery screening as well as assessing environmental endocrine disruption risk.

Learn More
Androgen Receptor Modulation Assay
New research on aldehyde oxidase and xanthine oxidase

At the 2016 International ISSX meeting, Phil Butler, Cyprotex's Head of ADME, presented a poster on the design of robust in vitro methods to study aldehyde oxidase and xanthine oxidase activity.

Download the poster
AOX and XO metabolic activity
3D microtissue model for assessing hypertrophy and structural cardiotoxicity
In this poster presented at the 2016 International ISSX meeting by Cyprotex's CSO, Clive Dilworth, we discuss the utility of 3D microtissues for the detection of drug-induced structural cardiac damage and hypertrophy.

Download the poster
Microtissue Cardiotoxicity Assay
Exploring substrates for studying rosuvastatin DDI risk
Estrone 3-sulphate is an accepted probe substrate for BCRP inhibition testing, but its potential as an in vitro experimental substrate for predicting rosuvastatin DDI was unproven. Senior Research Scientist, Hayley Jones, presented this poster at the Clinically Relevant Drug Transporters meeting in Berlin earlier this month.

Download the poster
Rosuvastatin drug-drug interaction
Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.